LP 007
Alternative Names: LP-007Latest Information Update: 06 Apr 2022
At a glance
- Originator Lepu Biopharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 06 Apr 2022 Preclinical trials in Haematological malignancies in USA (Parenteral) before April 2022 (Lepu Biopharma pipeline, April 2022)
- 06 Apr 2022 Preclinical trials in Solid tumours in China (Parenteral) before April 2022 (Lepu Biopharma pipeline, April 2022)
- 01 Apr 2022 Lepu Biopharma plan to file an IND submission for LP 007 to the NMPA in 2022 in China